Embed Size (px)
Citation preview
ResultsPrevalence of insomnia varies widely between the screened 6 nations, with France (27%) and Netherlands (14%) occupying the opposite ends of the spectrum. Despite these differences, across all studied countries women are more often affected by sleeping disorders than men. For women the average (unadjusted) risk of suffering from insomnia is twice as high as for men. Also, age infl uences liability to sleeping problems. As shown in Chart-1, prevalence of insomnia increases with age and reaches peak level at the age of 50-54 years.
Independent of age and gender, a higher proportion of individuals with Insomnia are found to suffer from other comorbidities in comparison to the general population. Especially the risk of suffering from mental health problems in the insomnia group is more than two-times higher. Depending on the respective disease (and the individual medical history) sleeping disorder can be a cause or result of some of the observed comorbidities.
Evaluation of diagnosis, treatment and medication use revealed some key differences between these six countries; however, a common trend can be identifi ed: among those diagnosed with insomnia condition, general practitioners are the primary point of diagnoses as well as the primary source of treatment. But a majority of individuals who reported sleeping problems received neither diagnosis nor treatment. Consequently, nearly half of the affected individuals do not take any medication against their sleeping problems, whereupon women are more likely to take sleeping pills than men among the subset of medication users.
ConclusionsPrevalence of insomnia appears to be substantial in the studied European nations, with France bearing the most burden (one-in-fi ve and one-in-three males and females respectively in France suffered from this condition). Prevalence peaked among the 45-64 age-group across the countries. Females had substantially higher disease burden across the countries, amounting to as much as 1.5 to 2 times more than their male counterparts in certain age groups. A total patient management approach addressing the sleeping problem and the existing comorbidities may be necessary to alleviate the disease burden.
Prevalence of INSOMNIA in EuropeA Comparison of Six Countries
IntroductionInsomnia is a symptom of sleeping disorder. It is defi ned as a diffi culty in initiating or maintaining sleep, which decreases quantity and quality of sleep and with that quality of life. Lack of sleep can cause problems during the day, such as excessive sleepiness, complications with thinking clearly or staying focused. Chronic insomnia often leads to low mood or depressed feeling.
ObjectivesThe primary objective of this study was to assess the intra-European differences in prevalence, diagnosis, treatment and medication of insomnia. The second aim of this study was to screen the population in order to identify individuals suffering from insomnia for further surveys.
MethodsTNS Healthcare’s European Healthcare Panel of individuals in France, Germany, Italy, UK, Spain and the Netherlands were surveyed in 2007 and 2008 to assess disease burden at national level. The self-reported epidemiological data is representative of population gender and age (18-24, 25-34, 35-44, 45-54, 55-64, 65-69 yrs) strata in respective countries, ensured by sampling and intensive panel management.
The survey collected information on select health conditions (incl. insomnia / sleeping problems; in the past 12 months), quality of life and healthcare utilization. In total, about 240,000 adult individuals completed the survey in the six European nations.
Graphic-1: Insomnia in Europe
EHP 2007 / 2008, N = 237,354
Netherlands
Spain
Germany
France
UK
Italy
Chart-2: Prevalence of Selected Disease-Groups – A Comparison between Total Population and Group of Individuals Suffering from Insomnia / Sleeping Problems
Persons suffering from insomnia / sleeping problems Total population
EHP 2007 / 2008, N = 237,354
Siva Narayanan – TNS Healthcare, a Kantar Health Company, New York, USAPeter Potthoff, Bernd Guether, Claudia Kanitscheider, Inga-Verena Wiebers – TNS Healthcare, a Kantar Health Company, Munich, Germany
Ratio
0 10 20 30 40 50 60 70 80
Pain diseases 1.4
Mental health problems 2.4
Gastro Intestinal diseases 1.8
Mens and womens health 1.8
Skin diseases 1.4
Respiratory diseases 1.6
Musculoskeletal disease 1.8
Urology diseases 1.9
Eye diseases 1.7
Oncological diseases 1.9
Metabolism diseases 1.5
Infection diseases 1.9
Percentages
EHP 2007 / 2008, N = 237,354
Chart-1: Prevalence of Insomnia and Consumption of Sleeping Pills
Consumption of sleeping pills – male
Insomnia / sleeping problems – male
Consumption of sleeping pills – female
Insomnia / sleeping problems – female
40
35
30
25
20
15
10
5
018-19 25-29 30-34 35-39 40-44 50-54 55-59 60-64 65-6945-4920-24
Age (years)
Per
cent
ages
TNS Healthcare, a Kantar Health Company // Siva Narayanan, MS MHS Ph: +1 203 434 9581 Em: [email protected] // Peter Potthoff, MD Ph: +49 (0)89 5600 1370 Em: [email protected]
Chart-3: Treatment of Insomnia / Sleeping Problems
General practitioner /family doctor
Specialist / hospital /medical care centre
Only self-medication Not medically treated
EHP 2007 / 2008, N = 52,569
60
50
40
30
20
10
0
Per
cent
ages
UK
524
52
Netherlands
20
8 19
53
Germany
1712
18
53
Italy
23
1814
45
France
32
7
4813
Spain
2014
44
22
20
≥ 14%≥ 20%≥ 26%
Prevalence of insomnia
Dispersion by gender
FemaleMale
